Annual CFO
-$8.45 M
-$866.00 K-11.42%
December 1, 2023
Summary
- As of February 23, 2025, NRSN annual cash flow from operations is -$8.45 million, with the most recent change of -$866.00 thousand (-11.42%) on December 1, 2023.
- During the last 3 years, NRSN annual CFO has fallen by -$7.76 million (-1116.12%).
- NRSN annual CFO is now -1352.23% below its all-time high of -$582.00 thousand, reached on December 31, 2019.
Performance
NRSN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
September 1, 2024
Summary
- NRSN quarterly cash flow from operations is not available.
Performance
NRSN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
September 1, 2024
Summary
- NRSN TTM cash flow from operations is not available.
Performance
NRSN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NRSN Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -11.4% | - | - |
| 3 y3 years | -1116.1% | - | - |
| 5 y5 years | -1352.2% | - | - |
NRSN Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -449.2% | at low | ||||
| 5 y | 5-year | -1352.2% | at low | ||||
| alltime | all time | -1352.2% | at low |
NeuroSense Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2024 | - | -$5.75 M(+47.3%) | -$5.75 M(+47.3%) |
| Dec 2023 | -$8.45 M(+11.4%) | - | - |
| Jun 2023 | - | -$3.90 M(-8.9%) | -$3.90 M(-8.9%) |
| Dec 2022 | -$7.59 M(+392.9%) | - | - |
| Jun 2022 | - | -$4.29 M | -$4.29 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$1.54 M(+121.4%) | - | - |
| Jun 2021 | - | -$403.00 K(-100.0%) | $7.24 B(-0.0%) |
| Mar 2021 | - | $7.24 B | $7.24 B |
| Dec 2020 | -$695.00 K(+19.4%) | - | - |
| Dec 2019 | -$582.00 K | - | - |
FAQ
- What is NeuroSense Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for NeuroSense Therapeutics?
- What is NeuroSense Therapeutics annual CFO year-on-year change?
- What is the all time high quarterly CFO for NeuroSense Therapeutics?
- What is the all time high TTM CFO for NeuroSense Therapeutics?
What is NeuroSense Therapeutics annual cash flow from operations?
The current annual CFO of NRSN is -$8.45 M
What is the all time high annual CFO for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high annual cash flow from operations is -$582.00 K
What is NeuroSense Therapeutics annual CFO year-on-year change?
Over the past year, NRSN annual cash flow from operations has changed by -$866.00 K (-11.42%)
What is the all time high quarterly CFO for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high quarterly cash flow from operations is $7.24 B
What is the all time high TTM CFO for NeuroSense Therapeutics?
NeuroSense Therapeutics all-time high TTM cash flow from operations is $7.24 B